We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues.
CSL, CMXHFSummary: CSL Ltd is engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The Company produces life-saving and life-enhancing medicines that enable people around the world to live a normal healthy life. It is a specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent serious and rare medical conditions. The Company's areas of expertise are Plasma Products: Human plasma is used to produce a wide range of life-saving medicines. The key businesses involved with plasma products include: CSL Behring and CSL Behring (Australia). Vaccines & Pharmaceuticals: manufactures and provides influenza vaccine. The Company's segments are CSL Behring: manufactures, markets and develops plasma therapies (plasma products and recombination's); biosCSL: manufactures and distributes non-plasma biotherapeutic products and CSL Intellectual Property: revenue & associated expenses from the licensing if Intellectual Property generated by the group to unrelated third parties and Research & Development expenses. The Company operates in four geographical areas, namely Australia, USA, Switzerland and Germany.
- Recent CMXHF Stock Price: $185.80
- Yearly Gain for CMXHF stock: -17.61%
- Market Cap for CMXHF stock: $89.04B
- P/E Ratio for CMXHF stock: 38.071
Will CMXHF's stock price go up? Is there an accurate CMXHF stock forecast available?
TipRanks.com reports that CSL currently has 12 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $210.84. The target pricing ranges from a high CMXHF forecast of $222.09 down to a low forecast of $188.67. CSL (CMXHF)’s last closing stock price was $185.80 which would put the average price target at 13.48% upside.
In addition, TradingView issued a n/a rating for CMXHF stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on CMXHF stock.
Other analysts covering CMXHF include:
- David Stanton of Jefferies issued a Buy rating with the price target of $ 209 on 4 days ago
- Andrew Paine of CLSA issued a Buy rating with the price target of $ 212.59 on 6 days ago
- Sean Laaman of Morgan Stanley issued a Buy rating with the price target of $ 210.63 on 1 week ago
- David Bailey of Macquarie issued a Buy rating with the price target of $ 214.87 on 1 week ago
If you are wondering if CMXHF is a good stock to buy, here are 3rd party ratings for CMXHF stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: sell
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding CSL? (Current ratings compiled by TipRanks.com)
- News Sentiment for CMXHF stock: Bullish
- Blogger Consensus for CMXHF stock: Bullish
- Media Buzz for CMXHF stock: Medium
- Insider Signal for CMXHF stock: Negative
- Investor Sentiment for CMXHF stock: ―
- Hedge Fund signal for CMXHF stock: No Signal
The stock market is extremely volatile, and you need to do your own research on CMXHF stock including scouring the social networks like CMXHF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CMXHF stock chart >>
Summary: Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.
- Recent ARQT Stock Price: $18.49
- Yearly Gain for ARQT stock: -21.54%
- Market Cap for ARQT stock: $1.10B
- P/E Ratio for ARQT stock: -3.541
Will ARQT's stock price go up? Is there an accurate ARQT stock forecast available?
TipRanks.com reports that Arcutis Biotherapeutics currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $51.00. The target pricing ranges from a high ARQT forecast of $61.00 down to a low forecast of $46.00. Arcutis Biotherapeutics (ARQT)’s last closing stock price was $18.49 which would put the average price target at 175.82% upside.
In addition, TradingView issued a n/a rating for ARQT stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ARQT stock.
Other analysts covering ARQT include:
- Uy Ear of Mizuho Securities issued a Buy rating with the price target of $ 61 on 1 day ago
- Vikram Purohit of Morgan Stanley issued a Buy rating with the price target of $ 46 on 1 day ago
- Sean Kim PhD of JonesTrading issued a Buy rating with the price target of $ 54 on 6 days ago
- Chris Shibutani of Goldman Sachs issued a Buy rating with the price target of $ 50 on 1 month ago
If you are wondering if ARQT is a good stock to buy, here are 3rd party ratings for ARQT stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 34% (84 out of 251)
What is the sentiment on the street regarding Arcutis Biotherapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARQT stock: Very Bullish
- Blogger Consensus for ARQT stock: Bullish
- Media Buzz for ARQT stock: Medium
- Insider Signal for ARQT stock: Neutral
- Investor Sentiment for ARQT stock: Very Positive
- Hedge Fund signal for ARQT stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ARQT stock including scouring the social networks like ARQT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARQT stock chart >>
Summary: Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States.
- Recent RCKT Stock Price: $13.36
- Yearly Gain for RCKT stock: -61.85%
- Market Cap for RCKT stock: $828.93M
- P/E Ratio for RCKT stock: -4.227
Will RCKT's stock price go up? Is there an accurate RCKT stock forecast available?
TipRanks.com reports that Rocket Pharmaceuticals currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $46.25. The target pricing ranges from a high RCKT forecast of $62.00 down to a low forecast of $24.00. Rocket Pharmaceuticals (RCKT)’s last closing stock price was $13.36 which would put the average price target at 246.18% upside.
In addition, TradingView issued a n/a rating for RCKT stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on RCKT stock.
Other analysts covering RCKT include:
- Geulah Livshits of Chardan Capital issued a Buy rating with the price target of n/a on 1 week ago
- Mani Foroohar of SVB Securities issued a Buy rating with the price target of n/a on 1 week ago
- Timur Ivannikov of Raymond James issued a Buy rating with the price target of $ 24 on 1 month ago
- Patrick Dolezal of LifeSci Capital issued a Buy rating with the price target of $ 43 on 1 month ago
If you are wondering if RCKT is a good stock to buy, here are 3rd party ratings for RCKT stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 34% (84 out of 251)
What is the sentiment on the street regarding Rocket Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for RCKT stock: Very Bullish
- Blogger Consensus for RCKT stock: Bullish
- Media Buzz for RCKT stock: Medium
- Insider Signal for RCKT stock: ―
- Investor Sentiment for RCKT stock: Neutral
- Hedge Fund signal for RCKT stock: Positive
The stock market is extremely volatile, and you need to do your own research on RCKT stock including scouring the social networks like RCKT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RCKT stock chart >>
Summary: Sotera Health Company is a provider of mission-critical end-to-end sterilization solutions and lab testing as well as advisory services for the healthcare industry. The company market through businesses which include Sterigenics(R), Nordion(R) and Nelson Labs(R). Sotera Health Company is Sotera Health Company is based in CLEVELAND.
- Recent SHC Stock Price: $7.25
- Yearly Gain for SHC stock: -72.01%
- Market Cap for SHC stock: $2.04B
- P/E Ratio for SHC stock: 16.689
Will SHC's stock price go up? Is there an accurate SHC stock forecast available?
TipRanks.com reports that Sotera Health currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $16.25. The target pricing ranges from a high SHC forecast of $25.00 down to a low forecast of $9.00. Sotera Health (SHC)’s last closing stock price was $7.25 which would put the average price target at 124.14% upside.
In addition, TradingView issued a n/a rating for SHC stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SHC stock.
Other analysts covering SHC include:
- Casey Woodring of J.P. Morgan issued a Sell rating with the price target of $ 9 on 6 days ago
- Amit Hazan of Goldman Sachs issued a Hold rating with the price target of $ 9 on 1 week ago
- Luke Sergott of Barclays issued a Hold rating with the price target of $ 22 on 1 week ago
- Sean Dodge of RBC Capital issued a Buy rating with the price target of $ 25 on 1 month ago
If you are wondering if SHC is a good stock to buy, here are 3rd party ratings for SHC stock:
- TipRanks.com: Hold
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Bottom 36% (161 out of 251)
What is the sentiment on the street regarding Sotera Health? (Current ratings compiled by TipRanks.com)
- News Sentiment for SHC stock: Very Bearish
- Blogger Consensus for SHC stock: ―
- Media Buzz for SHC stock: Very High
- Insider Signal for SHC stock: ―
- Investor Sentiment for SHC stock: Very Positive
- Hedge Fund signal for SHC stock: Negative
The stock market is extremely volatile, and you need to do your own research on SHC stock including scouring the social networks like SHC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SHC stock chart >>
Summary: Artivion Inc. is a medical device company. It focused on developing simple, elegant solutions which address cardiac and vascular surgeons. The company's group of products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts and surgical sealants. Artivion Inc., formerly known as CryoLife Inc., is headquartered in suburban Atlanta, Georgia.
- Recent AORT Stock Price: $14.06
- Yearly Gain for AORT stock: -41.37%
- Market Cap for AORT stock: $553.14M
- P/E Ratio for AORT stock: -29.581
Will AORT's stock price go up? Is there an accurate AORT stock forecast available?
TipRanks.com reports that Artivion currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $25.25. The target pricing ranges from a high AORT forecast of $32.00 down to a low forecast of $16.00. Artivion (AORT)’s last closing stock price was $14.06 which would put the average price target at 79.59% upside.
In addition, TradingView issued a n/a rating for AORT stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AORT stock.
Other analysts covering AORT include:
- Suraj Kalia of Oppenheimer issued a Buy rating with the price target of $ 25 on 1 day ago
- Cecilia Furlong of Morgan Stanley issued a Hold rating with the price target of $ 16 on 1 day ago
- Michael Matson of Needham issued a Buy rating with the price target of $ 28 on 1 day ago
- Rick Wise of Stifel Nicolaus issued a Buy rating with the price target of $ 30 on 6 months ago
If you are wondering if AORT is a good stock to buy, here are 3rd party ratings for AORT stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Bottom 30% (175 out of 251)
What is the sentiment on the street regarding Artivion? (Current ratings compiled by TipRanks.com)
- News Sentiment for AORT stock: Very Bullish
- Blogger Consensus for AORT stock: ―
- Media Buzz for AORT stock: Medium
- Insider Signal for AORT stock: Negative
- Investor Sentiment for AORT stock: ―
- Hedge Fund signal for AORT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on AORT stock including scouring the social networks like AORT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AORT stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================